The article, entitled “Rare diseases and Paediatrics: the goals of the Consorzio per Valutazioni Biologiche e Farmacologiche – Clinical Trial, development of new methodologies and innovative drugs”, is an interview to Donato Bonifazi (CEO of CVBF), who has outlined the main areas of interest and the activities undertaken by CVBF. Among the activities and the European initiatives coordinated by the Consortium in the field of paediatric clinical research, it was mentioned also the DEEP study, and the effort of both the European and non-European Countries of the Mediterranean area, participating in the trial, in order to demonstrate the safety and efficacy of deferiprone even in the smallest patients. In this scenario, explains Dr. Bonifazi, a special attention is given to Albania, for the potentials that this country offers in clinical research (and especially in paediatrics).

Finally the article has highlighted one of the main goals of the Consortium and the partners involved, consisting in the promotion of a European infrastructure of paediatric research, to encourage the connections and  the enhancement of research activities, thus contributing to the business development of the paediatric field in Europe.

Here you can download the complete article.